Results 111 to 120 of about 45,428 (223)

IgG4 anti‐CD47: Erythrophagocytosis and potential transfusion complications

Transfusion, EarlyView.
Abstract Background IgG4 monoclonal anti‐CD47 for cancer immunotherapy resulted in anemia necessitating red cell (RBC) transfusions. Although the antibody readily binds to CD47 on RBCs, the mechanism underlying the anemia associated with IgG4 is poorly understood.
Kayluz Frias Boligan, Melika Loriamini, Mairead B. Holton, Gurleen Sandhu, Beth Binnington, Randall Velliquette, Connie M. Westhoff, Donald R. Branch   +7 more
wiley   +1 more source

How Regulation and Global Standing Shape Stock Market Co‐Movements: A G20 Panel Study

International Review of Finance, Volume 26, Issue 2, June 2026.
ABSTRACT Motivated by post‐2020 fragmentation and underexplored institutional‐geopolitical drivers, we examine how regulatory quality (RQ) and global power (GP) shape stock‐market co‐movements across 17 G20 economies. We estimate time‐varying correlations via ADCC‐GARCH, construct a scaled correlation index, and apply panel ARDL. We find that higher RQ
Sama Haddad, Rakesh Gupta, E. A. Selvanathan, Saroja Selvanathan, Tarlok Singh   +4 more
wiley   +1 more source

Programmable Antigen‐Specific Immunity via Self‐Adjuvanting Nanovaccines Co‐Delivering Immune Modulators

Angewandte Chemie, Volume 138, Issue 11, 9 March 2026.
The self‐adjuvanting vaccine—comprising a covalent conjugate of antigen and adjuvant—was formulated into cationic lipid nanoparticles smaller than 100 nm to facilitate uptake by immune cells, with supplemental adjuvants incorporated to modulate immune responses.
Keita Ito, Yoshiyuki Manabe, Shino Ohshima, Masatoshi Maeki, Manabu Tokeshi, Hiroshi Inaba, Kazunori Matsuura, Kazuya Kabayama, Yoshie Kametani, Koichi Fukase   +9 more
wiley   +2 more sources

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.

PLoS ONE, 2018
Because human epidermal growth factor-like receptor (HER) 2 is expressed on the surface of human pancreatic carcinoma cells to varying degrees, trastuzumab, an anti-HER2 monoclonal antibody (mAb), is expected to exert antibody-dependent, natural killer ...
Takushi Masu, Masanori Atsukawa, Katsuhisa Nakatsuka, Masumi Shimizu, Daishu Miura, Taeang Arai, Hirotomo Harimoto, Chisa Kondo, Keiko Kaneko, Seiji Futagami, Chiaki Kawamoto, Hidemi Takahashi, Katsuhiko Iwakiri   +12 more
doaj   +1 more source

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis

European Journal of Immunology, Volume 56, Issue 4, April 2026.
Current plasma cell–targeting therapies lack antigen specificity. Using an antibody‐mediated cytotoxicity engager (ACE) targeting the α‐subunit of the extracellular domain of the human acetylcholine receptor (hAChR αECD), we selectively depleted pathogenic antibody‐secreting cells in a myasthenia gravis model, reducing autoantibody titers and disease ...
Laleh Khodadadi, Deborah Puppe, Dilara S. Cirillo, Carolina Martinez‐Cingolani, Jens Klotsche, Andreas Pelz, Siegfried Kohler, Qingyu Cheng, Konstantinos Lazaridis, Michael Fichtner, Jan Pille, Andrey Kruglov, Marina Bondareva, Tobias Alexander, Andreas Radbruch, Andreas Meisel, Falk Hiepe   +16 more
wiley   +1 more source

Correlation Dynamics in European Equity Markets [PDF]

We examine correlation dynamics using daily data from 1993 to 2002 on the 5 largest eurozone stock market indices. We also study, for comparison, the correlations of a sample of individual stocks.
Colm Kearney, Valerio Poti
core  

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Effects of in vivo treatment with FK506 on natural killer cells in rats [PDF]

, 1991
Fung, JJ, Hiserodt, JC, Luchs, BA, Markus, PM, Starzl, TE, Van Den Brink, MRM   +5 more
core   +1 more source

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

MedComm, Volume 7, Issue 4, April 2026.
Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu   +6 more
wiley   +1 more source